Opdivo-Yervoy (nivolumab-ipilimumab)

pCPA File Number: 21557
Negotiation Status:
Under consideration for negotiation
OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable malignant pleural mesothelioma (MPM) who have not received prior systemic therapy for MPM
Bristol Myers Squibb Canada Inc.
CADTH Project Number:
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable